title: [Specific immunotherapy].
abstract: SCIT (subcutaneous immunotherapy) and SLIT (sublingual immunotherapy) are the only routinely available therapies, which modify allergic diseases sustainably. The ongoing reduction of symptoms and the lower need of symptomatic medication are able to improve the quality of life over a long period of time. However, allergic patients are underprovided due to low use of SIT (specific immunotherapy). After thorough diagnostic workup, the indication has to be checked carefully especially in patients with allergic rhinitis and allergic asthma, to insure that SIT is standard therapy. Allergen extracts are manufacturer-specific preparations, therefore their effects cannot be compared directly, just as SCIT and SLIT efficacy cannot be compared directly. In general, preparations with proven efficacy and safety profile should be preferred. Allergens listed in the TAV (Therapeutic Allergen Regulation) fulfill these requirements. However, it is important to ensure adherence for 3 years of therapy, independent of the route of application. SIT has proven socioeconomic benefit already after a short time of therapy.
authors.affiliation: Klinik und Poliklinik für Dermatologie, Universitätsklinikum Münster, Von-Esmarch-Str. 58, 48149, Münster, Deutschland, sonja.grundmann@ukmuenster.de.
authors.forename: S A
authors.initials: SA
authors.lastname: Grundmann
authors.forename: P
authors.initials: P
authors.lastname: Mosters
authors.forename: R
authors.initials: R
authors.lastname: Brehler
mesh_terms: D000284:Administration, Oral; D000287:Administration, Topical; D000485:Allergens / Q000008:administration & dosage* / Q000276:immunology; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D065631:Rhinitis, Allergic / Q000188:drug therapy* / Q000276:immunology; D063729:Sublingual Immunotherapy / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000485:Allergens